Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Citicoline in non-arteritic anterior ischemic optic neuropathy
IRCT20240107060637N1Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of citicoline in non-arteritic anterior ischemic optic neuropathy (NAION), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Ganglion cell layer thickness, Optic nerve fiber layer thickness and 3 more. Started Jan 2024; status: completed.
02
Drugs
citicoline
03
Conditions
non-arteritic anterior ischemic optic neuropathy (NAION)
Beyond the preview
Go deeper on IRCT20240107060637N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240107060637N1.